Thus, although the difference between sexes in acute-phase s-IGF-II appears to have some implications for poststroke functional outcomes, it is undoubtedly attenuated by age and cardiovascular covariates (Models A and B) and fades into small, non-significant ORs after adjustment for stroke severity (Model C; Table 3). This evidence concerns the gene IGF2 and Stroke.